Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Oramed Pharmaceuticals Inc. Director's Dealing 2022

May 4, 2022

6965_rns_2022-05-04_115a9775-4f48-4db4-b60b-fda12f19b809.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4
------------ --

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).
Check this box if no longer subject to STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
OMB Number:
3235-0287
Estimated average burden
hours per response:
0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
1. Name and Address of Reporting Person*
Rozov Yadin
(Last)
(First)
(Middle)
1185 AVENUE OF THE AMERICAS, THIRD
FLOOR
2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC. [
ORMP ]
(Check all applicable)
X
Director
Officer (give title 5. Relationship of Reporting Person(s) to Issuer
10% Owner
Other (specify
3. Date of Earliest Transaction (Month/Day/Year)
05/02/2022
below) below)
(Street)
NEW YORK
NY
10036
4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable
Line)
X
Form filed by One Reporting Person
Form filed by More than One Reporting
Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)
2. Transaction
Date
(Month/Day/Year) 2A. Deemed
Execution Date,
if any
(Month/Day/Year)
3.
8)
Transaction
Code (Instr.
5)
4. Securities Acquired (A) or
Disposed Of (D) (Instr. 3, 4 and
5. Amount of
Securities
Beneficially
Owned Following
Reported
6. Ownership
Form: Direct
(D) or Indirect
(I) (Instr. 4)
7. Nature
of Indirect
Beneficial
Ownership
(Instr. 4)
Code V Amount (A) or
(D)
Price Transaction(s)
(Instr. 3 and 4)
Common Stock 05/02/2022 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
A 4,500 A (1) 4,500 D
1. Title of
Derivative
Security
(Instr. 3)
2.
Conversion
or Exercise
Price of
Derivative
Security
3. Transaction
Date
(Month/Day/Year)
3A. Deemed
Execution Date,
if any
(Month/Day/Year)
4.
5. Number
Transaction
of
Code (Instr.
Derivative
8)
Securities
Acquired
(A) or
Disposed
6. Date Exercisable and
7. Title and
Expiration Date
Amount of
(Month/Day/Year)
Securities
Underlying
Derivative Security
(Instr. 3 and 4)
8. Price of
Derivative
Security
(Instr. 5)
9. Number of
derivative
Securities
Beneficially
Owned
Following
Reported
10.
Ownership
Form:
Direct (D)
or Indirect
(I) (Instr. 4)
11. Nature
of Indirect
Beneficial
Ownership
(Instr. 4)
Security (A) or
Disposed
of (D)
(Instr. 3, 4
and 5)
(Instr. 3 and 4) Following
Reported
Transaction(s)
(Instr. 4)
(I) (Instr. 4)
Code V (A) (D) Date
Exercisable
Expiration
Date
Title Amount
or
Number
of
Shares
Stock
Option
(right to
buy)
\$5.14 05/02/2022 A 7,500 (2) 05/02/2032 Common Stock 7,500 \$0 7,500 D

Explanation of Responses:

  1. Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 1,125 shall vest on each of May 2, 2023, May 2, 2024, May 2, 2025 and May 2, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

  2. The Stock Option will vest in 4 installments as follows: 1,875 shall vest on each of May 2, 2023, May 2, 2024, May 2, 2025 and May 2, 2026.

/s/ Yadin Rozov 05/03/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.